| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | Keio Journal of Medicine |
| Volume | 59 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2010 |
Fingerprint
21st Century History
19th Century History
20th Century History
Piperazines
Pyrimidines
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Biomedical Research
Leukemia
Neoplasms
Therapeutics
Imatinib Mesylate
Keywords
- CML
- Imanitib
- Leukemia
- Molecularly targeted therapy
ASJC Scopus subject areas
- Medicine(all)
Cite this
Imatinib (Gleevec®) as a paradigm of targeted cancer therapies. / Druker, Brian.
In: Keio Journal of Medicine, Vol. 59, No. 1, 03.2010, p. 1-3.Research output: Contribution to journal › Article
Druker, B 2010, 'Imatinib (Gleevec®) as a paradigm of targeted cancer therapies', Keio Journal of Medicine, vol. 59, no. 1, pp. 1-3. https://doi.org/10.2302/kjm.59.1
@article{4164111c9bd842cc94e2964f99cb9caa,
title = "Imatinib (Gleevec{\circledR}) as a paradigm of targeted cancer therapies",
keywords = "CML, Imanitib, Leukemia, Molecularly targeted therapy",
author = "Brian Druker",
year = "2010",
month = "3",
doi = "10.2302/kjm.59.1",
language = "English (US)",
volume = "59",
pages = "1--3",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "1",
}
TY - JOUR
T1 - Imatinib (Gleevec®) as a paradigm of targeted cancer therapies
AU - Druker, Brian
PY - 2010/3
Y1 - 2010/3
KW - CML
KW - Imanitib
KW - Leukemia
KW - Molecularly targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=77954302007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954302007&partnerID=8YFLogxK
U2 - 10.2302/kjm.59.1
DO - 10.2302/kjm.59.1
M3 - Article
C2 - 20375651
AN - SCOPUS:77954302007
VL - 59
SP - 1
EP - 3
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
SN - 0022-9717
IS - 1
ER -